| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1572-0241.2005.41794.X |
| P698 | PubMed publication ID | 15984978 |
| P50 | author | Richard N. Fedorak | Q43531400 |
| Massimo Campieri | Q54867165 | ||
| Paolo Gionchetti | Q57069528 | ||
| P2093 | author name string | R Balfour Sartor | |
| Claudio De Simone | |||
| Karen L Madsen | |||
| Gerald W Tannock | |||
| Rodrigo Bibiloni | |||
| P2860 | cites work | Treatment of ulcerative colitis using fecal bacteriotherapy | Q28179819 |
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial | Q28213579 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. | Q33786301 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis | Q33989634 | ||
| Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces | Q34101794 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis | Q35596664 | ||
| Probiotics and the management of inflammatory bowel disease. | Q35854517 | ||
| Probiotics and prebiotics in gastrointestinal disorders. | Q36036491 | ||
| Impact of consumption of oligosaccharide-containing biscuits on the fecal microbiota of humans | Q37318619 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. | Q43746137 | ||
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 | ||
| Quantitative detection of probiotic Bifidobacterium strains in bacterial mixtures by using real-time PCR. | Q44515740 | ||
| DNA from probiotic bacteria modulates murine and human epithelial and immune function | Q47635337 | ||
| Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction | Q47809423 | ||
| Probiotics | Q57241205 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| probiotics | Q1816730 | ||
| P304 | page(s) | 1539-1546 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis | |
| P478 | volume | 100 |
| Q47163293 | A New Proposal for the Pathogenic Mechanism of Non-Coeliac/Non-Allergic Gluten/Wheat Sensitivity: Piecing Together the Puzzle of Recent Scientific Evidence |
| Q30830505 | A key role of dendritic cells in probiotic functionality |
| Q56379902 | A probiotic modulates the microbiome and immunity in multiple sclerosis |
| Q36699182 | Actual concept of "probiotics": is it more functional to science or business? |
| Q38447464 | Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice |
| Q44967584 | Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition |
| Q33908943 | Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1. |
| Q37256009 | Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells |
| Q54346651 | Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. |
| Q42725926 | Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. |
| Q34387493 | Anti-inflammatory properties of Streptococcus salivarius, a commensal bacterium of the oral cavity and digestive tract. |
| Q38876416 | Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice |
| Q33867934 | Antibiotics and probiotics in treatment of inflammatory bowel disease. |
| Q33416742 | Application of sequence-dependent electrophoresis fingerprinting in exploring biodiversity and population dynamics of human intestinal microbiota: what can be revealed? |
| Q39127400 | Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases |
| Q90390539 | Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis |
| Q36720493 | Bacteria and mucosal immunity. |
| Q42580341 | Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. |
| Q35719834 | Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner |
| Q51035866 | Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. |
| Q35832867 | Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children |
| Q64953955 | Changes in the intestinal microecology induced by bacillus subtilis inhibit the occurrence of ulcerative colitis and associated cancers: a study on the mechanisms. |
| Q26769032 | Clinical Uses of Probiotics |
| Q45119053 | Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis. |
| Q35015672 | Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism |
| Q44623193 | Comparative in vitro inhibition of urinary tract pathogens by single- and multi-strain probiotics |
| Q28537737 | Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease |
| Q53188361 | Competence and sporulation factor derived from Bacillus subtilis improves epithelial cell injury in intestinal inflammation via immunomodulation and cytoprotection. |
| Q96304874 | Complementary and alternative medications in the management of inflammatory bowel disease |
| Q26768564 | Diet therapy for inflammatory bowel diseases: The established and the new |
| Q36645416 | Dietary Geraniol by Oral or Enema Administration Strongly Reduces Dysbiosis and Systemic Inflammation in Dextran Sulfate Sodium-Treated Mice |
| Q54441343 | Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. |
| Q47404257 | Differential suppression of heat-killed lactobacilli isolated from kimchi, a Korean traditional food, on airway hyper-responsiveness in mice |
| Q33648530 | Diversity: from diet to flora to life |
| Q36687466 | Drug therapy of inflammatory bowel disease in fertile women |
| Q36974913 | Effect of a probiotic on prevention of diarrhea and Clostridium difficile and Clostridium perfringens shedding in foals |
| Q46143449 | Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis |
| Q55363098 | Effect of administration of a probiotic preparation on gut microbiota and immune response in healthy women in India: an open-label, single-arm pilot study. |
| Q55317992 | Effect of fermented vegetable beverage containing Pediococcus pentosaceus in patients with mild to moderate ulcerative colitis. |
| Q35161765 | Effect of live Salmonella Ty21a in dextran sulfate sodium-induced colitis |
| Q39753061 | Effect of oral administration of Butyrivibrio fibrisolvens MDT-1 on experimental enterocolitis in mice |
| Q33300590 | Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies |
| Q35625435 | Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis |
| Q37118873 | Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis |
| Q36039436 | Emerging drugs for the treatment of ulcerative colitis |
| Q39692232 | Entrapment of Lactobacillus acidophilus into alginate beads for the effective treatment of cold restraint stress induced gastric ulcer. |
| Q46620197 | Evaluation of the preventative effects exerted by Lactobacillus fermentum in an experimental model of septic shock induced in mice. |
| Q34652744 | Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. |
| Q45160532 | Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice |
| Q57124109 | Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease |
| Q28251016 | Fecal microbiota transplantation: current status and future directions |
| Q37334837 | FolC2-mediated folate metabolism contributes to suppression of inflammation by probiotic Lactobacillus reuteri |
| Q35271319 | Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease |
| Q24682955 | Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius |
| Q36531260 | Gastrointestinal microflora: probiotics |
| Q37228128 | GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis |
| Q38794312 | Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. |
| Q37682520 | Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome |
| Q28238138 | Gut bacteria in health and disease |
| Q35025946 | Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target |
| Q26995672 | Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility |
| Q35963727 | Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India |
| Q35670894 | Gut microbiota and inflammation |
| Q35228714 | Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management |
| Q37858913 | Gut microbiota, probiotics and inflammatory bowel disease. |
| Q33666412 | Gut microbiota, probiotics, and human health |
| Q37082773 | Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease |
| Q37828084 | Health benefits of probiotics: are mixtures more effective than single strains? |
| Q35795929 | Host lysozyme-mediated lysis of Lactococcus lactis facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons |
| Q28743610 | Identification and characterisation of an iron-responsive candidate probiotic |
| Q38414874 | Immunohistochemical Analysis of Carbohydrate Antigens in Chronic Inflammatory Gastrointestinal Diseases |
| Q36587241 | Immunomodulatory Activity of Lactococcus lactis A17 from Taiwan Fermented Cabbage in OVA-Sensitized BALB/c Mice |
| Q33632901 | Immunomodulatory activity of two potential probiotic strains in LPS-stimulated HT-29 cells |
| Q42489021 | Immunomodulatory effects of Lactobacillus casei administration in a mouse model of gliadin-sensitive enteropathy. |
| Q42487704 | Immunoprotective Effect of Probiotic Dahi Containing Lactobacillus acidophilus and Bifidobacterium bifidum on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice |
| Q43162041 | Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis |
| Q39604749 | Impact of a probiotic Enterococcus faecalis in a gnotobiotic mouse model of experimental colitis |
| Q37781315 | Importance of disrupted intestinal barrier in inflammatory bowel diseases |
| Q37182945 | Importance of nutrition in inflammatory bowel disease |
| Q38136473 | In vivo reprogramming in inflammatory bowel disease |
| Q37969593 | Indications for the use of probiotics in gastrointestinal diseases |
| Q38797790 | Indigo Naturalis Ameliorates Oxazolone-Induced Dermatitis but Aggravates Colitis by Changing the Composition of Gut Microflora |
| Q36631518 | Inflammatory bowel disease: Pandora's box, present and future |
| Q51759202 | Influence of Altered Gut Microbiota Composition on Aging and Aging-Related Diseases. |
| Q30445894 | Innate and adaptive immune responses related to IBD pathogenesis |
| Q33314436 | Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy |
| Q33534036 | Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children |
| Q27003192 | Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease |
| Q38727911 | Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. |
| Q35245299 | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease |
| Q38268672 | Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? |
| Q27015884 | Intestinal permeability--a new target for disease prevention and therapy |
| Q50146310 | Investigation of probiotics in multiple sclerosis |
| Q42004558 | Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats. |
| Q45227059 | Lactic acid bacteria and bifidobacteria attenuate the proinflammatory response in intestinal epithelial cells induced by Salmonella enterica serovar Typhimurium |
| Q36185519 | Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study |
| Q36811334 | Lactobacillus acidophilus stimulates intestinal P-glycoprotein expression via a c-Fos/c-Jun-dependent mechanism in intestinal epithelial cells |
| Q85089824 | Lactobacillus gasseri suppresses Th17 pro-inflammatory response and attenuates allergen-induced airway inflammation in a mouse model of allergic asthma |
| Q41877251 | Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. |
| Q33767034 | Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation |
| Q53828672 | Lactobacillus reuteri increases mucus thickness and ameliorates dextran sulphate sodium-induced colitis in mice. |
| Q79938281 | Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy |
| Q33928149 | Lactobacillus saerimneri and Lactobacillus ruminis: novel human-derived probiotic strains with immunomodulatory activities |
| Q36739682 | Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. |
| Q21562212 | Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment |
| Q42909606 | Maintaining adequate nutrition, not probiotic administration, prevents growth stunting and maintains skeletal muscle protein synthesis rates in a piglet model of colitis |
| Q22251072 | Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis |
| Q37214848 | Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases |
| Q36609208 | Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials |
| Q37427481 | Medical treatment of ulcerative colitis |
| Q48168386 | Meta-Analysis of Fecal Microbiota and Metabolites in Experimental Colitic Mice during the Inflammatory and Healing Phases |
| Q37968291 | Microbes and microbial effector molecules in treatment of inflammatory disorders |
| Q37965684 | Microbes, intestinal inflammation and probiotics. |
| Q38130307 | Microbial activation of gut dendritic cells and the control of mucosal immunity |
| Q84006106 | Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis |
| Q37123770 | Microbial host interactions in IBD: implications for pathogenesis and therapy |
| Q36441742 | Microbial translocation across the GI tract |
| Q34292157 | Microbiome and immunological interactions |
| Q36239612 | Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage |
| Q35195891 | Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? |
| Q34131265 | Mucosal immunity in human and simian immunodeficiency lentivirus infections |
| Q38033092 | NSAID enteropathy: could probiotics prevent it? |
| Q35578935 | Novel microbiome-based therapeutics for chronic rhinosinusitis |
| Q39868711 | Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions |
| Q41949151 | Novel treatment options for ulcerative colitis |
| Q35646449 | Nutraceutical Supplements for Inflammatory Bowel Disease |
| Q27028202 | Nutritional protective mechanisms against gut inflammation |
| Q51614351 | Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. |
| Q38308253 | Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. |
| Q92889485 | PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE |
| Q53585398 | Polyphosphate, an active molecule derived from probiotic Lactobacillus brevis, improves the fibrosis in murine colitis. |
| Q33406281 | Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation |
| Q34622765 | Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis |
| Q36885451 | Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system |
| Q35601294 | Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. |
| Q45805938 | Preventing bacteria-induced disease with bacteria |
| Q44414008 | Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes |
| Q34018243 | Probiotic Bio-Three induces Th1 and anti-inflammatory effects in PBMC and dendritic cells |
| Q39826904 | Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid |
| Q37543639 | Probiotic Microorganisms Inhibit Epithelial Cell Internalization of Botulinum Neurotoxin Serotype A. |
| Q29037475 | Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis |
| Q34170678 | Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis |
| Q30425823 | Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism |
| Q34503660 | Probiotic manipulation of the gastrointestinal microbiota |
| Q40447506 | Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. |
| Q94527883 | Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases |
| Q43095847 | Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10J mice |
| Q48677169 | Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study |
| Q37094595 | Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend? |
| Q33847243 | Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase |
| Q26800020 | Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases |
| Q43132126 | Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects |
| Q57109928 | Probiotics - do they have a role in the pig industry? |
| Q92570724 | Probiotics Upregulate Trefoil Factors and Downregulate Pepsinogen in the Mouse Stomach |
| Q94475534 | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model |
| Q34731103 | Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome |
| Q34162963 | Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science |
| Q47913026 | Probiotics and blueberry attenuate the severity of dextran sulfate sodium (DSS)-induced colitis |
| Q38125810 | Probiotics and clinical effects: is the number what counts? |
| Q37988434 | Probiotics and digestive disease |
| Q42234301 | Probiotics and ileitis: could augmentation of TNF/NFκB activity be the answer? |
| Q34013030 | Probiotics and prebiotics in chronic inflammatory bowel diseases |
| Q34588415 | Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. |
| Q37292430 | Probiotics and small bowel mucosa: Molecular aspects of their interactions |
| Q37150557 | Probiotics and the Microbiome in Celiac Disease: A Randomised Controlled Trial. |
| Q36567134 | Probiotics and the gut microbiota in intestinal health and disease |
| Q24242963 | Probiotics for induction of remission in ulcerative colitis |
| Q38009716 | Probiotics for the treatment of inflammatory bowel disease |
| Q82416873 | Probiotics in Gastrointestinal Disorders |
| Q37071265 | Probiotics in clinical practice: an overview |
| Q36720509 | Probiotics in experimental and human inflammatory bowel disease: discussion points |
| Q37492720 | Probiotics in pediatric inflammatory bowel diseases |
| Q59120479 | Probiotics in the Management of Inflammatory Bowel Diseases? |
| Q33438518 | Probiotics in the management of colonic disorders |
| Q36348570 | Probiotics in the management of inflammatory bowel disease. |
| Q34637606 | Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients |
| Q24630676 | Probiotics in the management of ulcerative colitis |
| Q36658938 | Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice |
| Q30437282 | Probiotics promote gut health through stimulation of epithelial innate immunity |
| Q36171266 | Probiotics to prevent the need for, and augment the use of, antibiotics |
| Q35131051 | Probiotics, nuclear receptor signaling, and anti-inflammatory pathways |
| Q33445442 | Probiotics. |
| Q35637895 | Probiotics: The scientific evidence in the context of inflammatory bowel disease |
| Q36631503 | Probiotics: do they help to control intestinal inflammation? |
| Q36759892 | Proposed model: mechanisms of immunomodulation induced by probiotic bacteria |
| Q49024396 | Protective effects of Lactobacillus rhamnosus [corrected] and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve |
| Q46340421 | Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease |
| Q37345932 | Rationale for probiotic treatment strategies in inflammatory bowel disease |
| Q58796769 | Rebuilding the Gut Microbiota Ecosystem |
| Q36804314 | Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease? |
| Q42730491 | Recent advances in the management of distal ulcerative colitis |
| Q34596752 | Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment |
| Q34411373 | Recommendations for probiotic use in humans-a 2014 update |
| Q54634996 | Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. |
| Q36559646 | Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics |
| Q37141846 | Role of probiotic therapy in IBD. |
| Q34583797 | Role of probiotics in correcting abnormalities of colonic flora induced by stress |
| Q37283590 | Role of sulfated O-glycans expressed by high endothelial venule-like vessels in pathogenesis of chronic inflammatory gastrointestinal diseases |
| Q24599062 | Role of the gut microbiota in defining human health |
| Q36886503 | Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ |
| Q34407175 | Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? |
| Q37058869 | Role of the intestinal barrier in inflammatory bowel disease |
| Q30423660 | SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis |
| Q35904302 | Safety and efficacy of Profermin® to induce remission in ulcerative colitis. |
| Q40328326 | Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. |
| Q64107231 | Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases |
| Q51793678 | Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. |
| Q57129555 | Small-intestinal manifestations of dextran sulfate sodium consumption in rats and assessment of the effects of Lactobacillus fermentum BR11 |
| Q42795386 | Specific immunotherapy plus Clostridium butyricum alleviates ulcerative colitis in patients with food allergy |
| Q37311673 | Stress as a Trigger for Relapses in IBD: A Case-Crossover Study |
| Q35690531 | Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis |
| Q33235512 | Supplementation of the diet with high-viscosity beta-glucan results in enrichment for lactobacilli in the rat cecum |
| Q38189500 | Systemic immune activation in HIV and potential therapeutic options. |
| Q33939802 | Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era |
| Q26784194 | Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases |
| Q64257282 | The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis |
| Q57492072 | The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease |
| Q34092270 | The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner |
| Q50899710 | The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis. |
| Q42038763 | The Role of Probiotics in IBD. |
| Q40231712 | The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells |
| Q43352809 | The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin |
| Q35008169 | The effect of probiotics and gut microbiota on Th17 cells |
| Q34955775 | The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis |
| Q38026552 | The emerging therapeutic role of probiotics in inflammatory bowel disease |
| Q35214930 | The gastrointestinal microbiome: a malleable, third genome of mammals |
| Q38876749 | The gut and oral microbiome in HIV disease: a workshop report. |
| Q28750959 | The human microbiome and probiotics: implications for pediatrics |
| Q35132150 | The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept) |
| Q36653913 | The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. |
| Q27001546 | The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials |
| Q38174603 | The role of probiotics and prebiotics in inducing gut immunity. |
| Q36712363 | The role of probiotics in inflammatory bowel disease |
| Q57245618 | The use of probiotics in gastrointestinal diseases |
| Q59792682 | Therapeutic Microbiology: The Role of as Food Supplement for the Prevention/Treatment of Paediatric Diseases |
| Q36549836 | Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease |
| Q42705209 | Therapeutic benefit of pentostatin in severe IL-10-/- colitis |
| Q39870352 | Therapeutic effect of Streptococcus thermophilus CRL 1190-fermented milk on chronic gastritis |
| Q37122235 | Therapeutic effects of four strains of probiotics on experimental colitis in mice |
| Q59792624 | Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells |
| Q37318035 | Therapeutic strategies for the management of ulcerative colitis. |
| Q54358058 | Toll-like receptor 2 monoclonal antibody or/and Toll-like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteria in dextran sulfate sodium-induced colitis in mice. |
| Q26853183 | Treatment of inflammatory bowel disease (IBD) |
| Q37058862 | Treatment of inflammatory bowel disease: a review of medical therapy |
| Q35233808 | Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. |
| Q38008899 | Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases |
| Q38055197 | Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs |
| Q93212631 | Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation |
| Q26825483 | Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier |
| Q36613876 | Update in the treatment of paediatric ulcerative colitis |
| Q38732337 | VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-γ-induced Intestinal Epithelial Barrier Defects |
| Q36563414 | VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases |
| Q35010644 | VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer |
| Q24651289 | VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation |
| Q44887797 | VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis |
| Q54588131 | VSL#3 probiotics provide protection against acute intestinal ischaemia/reperfusion injury. |
| Q45339638 | VSL#3 ® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis |
| Q33758617 | Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases |
| Q91827145 | You are what you eat: diet, health and the gut microbiota |
Search more.